{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
INN:alrefimotide [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:domvanalimab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00118274: Phase 1/Phase 2 Interventional Completed Melanoma (Skin)
(2005)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04348136: Phase 2/Phase 3 Interventional Active, not recruiting Mucopolysaccharidosis II
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:eltivutabart [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
NCT04322149: Phase 2 Interventional Completed Amyotrophic Lateral Sclerosis
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03406611: Phase 1/Phase 2 Interventional Active, not recruiting Homocystinuria
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03500380: Phase 2/Phase 3 Interventional Active, not recruiting Breast Neoplasms
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03530683: Phase 1 Interventional Terminated Lymphoma
(2018)
Source URL:
Class:
PROTEIN
